FUTURA MEDICAL PLC – Eu Market Launch Clearance
RNS Number : 6160O Futura Medical PLC 31 July 2026 31 July 2026 Futura Medical plc (“Futura”, “the Group”
Read More
FUTURA MEDICAL PLC – Highly Positive Data From Wsd4000 Studies
RNS Number : 2595K Futura Medical PLC 30 June 2026 30 June 2026 Futura Medical plc (“Futura”, “the Group”
FUTURA MEDICAL PLC – New Us Commercial Partner
RNS Number : 0758K Futura Medical PLC 29 June 2026 29 June 2026 Futura Medical plc (“Futura”, “the Group”
FUTURA MEDICAL PLC – Notice Of Results Investor Presentation
RNS Number : 0911B Futura Medical PLC 20 April 2026 20 April 2026 Futura Medical plc (“Futura” or
Four AIM strugglers with recovery potential
Our award-winning AIM expert discusses how some of 2019’s worst performers could bounce back this year.
Futura Medical PLC – AGM Statement
Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal Dermasys® drug delivery technology currently focused on sexual health and pain, is pleased to announce that John Clarke, Chairman, will provide an update at the Company’s Annual General Meeting held at 10am later today in London.
Futura Medical PLC – Patient Recruitment completed for MED2005 Phase 3 study
Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal Dermasys® drug delivery technology currently focused on sexual health and pain, is pleased to announce the completion of patient recruitment for the first European Phase 3 study, “FM57”, of MED2005.
Futura Medical PLC – Preliminary Results
Futura Medical plc (AIM: FUM), the pharmaceutical company developing a portfolio of innovative products for sexual health and pain, based on its proprietary, transdermal DermaSys® drug delivery technology is pleased to announce its preliminary results for the year ended 31 December 2018.
Futura Medical PLC – AGM Statement
Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology, will hold its Annual General Meeting in London today.
Futura Medical plc – Positive data from MED2002 PK study
Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology, is pleased to announce positive data from its pharmacokinetic (“PK”) study FM58 of MED2002, the Company’s topical gel for erectile dysfunction (“ED”). MED2002 contains glyceryl trinitrate (“GTN”) as its active ingredient.